Benefit-risk assessment: To quantify or not to quantify, that is the question

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 6, 2011, Pages 653-656

  Yuan, Zhong ^a   Levitan, Bennett ^a   Berlin, Jesse A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG EFFICACY; DRUG SAFETY; MEDICAL RESEARCH; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN;

EID: 79959542542     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2149     Document Type: Note

References (23)

1. AstraZeneca Receives Action Letter From FDA for Exanta (ximelagatran). [9 August 2010].
2. Merck Announces Voluntary Worldwide Withdrawal of VIOXX®. [9 August 2010].
3. Brower V. ESAs further restricted, but debate continues. J Natl Cancer Inst 2008; 100: 1344-51.
4. Eichler HG, Abadie E, Raine JM, Salmonson T. Safe drugs and the cost of good intentions. N Engl J Med 2009; 360: 1378-80.
5. Working CIOMS Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Council for International Organizations of Medical Sciences: Geneva, 1998.
6. EBE Report: Balancing Benefits and Risks: Sharing Responsibility. [12 August 2010].
7. Breckenridge A. Regulatory challenges, reimbursement, and risk-benefit assessment. Clin Pharmacol Ther 2010; 88: 153-4.
8. Walker S, Liberti L, McAuslane N. Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters. Clin Pharmacol Ther 2011; 89: 179-82.
9. European Medicines Agency Benefit-Risk Methodology Project, EMA/213482/2010 (2010). [16 February 2011].
10. Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther 2011; 89: 312-5.
11. Levitan BS, Andrews EB, Gilsenan A, et al. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther 2011; 89: 217-24.
12. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-33.
13. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-4.
14. Roukoz H, Bavry AA, Sarkees ML, et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med 2009; 122: 581.e1-581.e10.
15. Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. JAMA 1999; 281: 1836-43.
16. Holden WL, Juhaeri J, Dai W. Benefit-risk analysis: examples using quantitative methods. Pharmacoepidemiol Drug Saf 2003; 12: 693-7.
17. Unger EF. Weighing benefits and risks--the FDA's review of prasugrel. N Engl J Med 2009; 361: 942-5.
18. O'Neill RT. A perspective on characterizing benefits and risks derived from clinical trials: can we do more? Drug Inf J 2008; 42: 235-245.
19. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health 2010; 13: 657-66.
20. Benefit-risk Methodology Project: Work Package 2 Report: Applicability of Current Tools and Processes for Regulatory Benefit-risk Assessment. [16 February 2011].
21. Cost-Effectiveness Analysis (CEA) Registry. [17 February 2011].
22. Johnson FR, Hauber AB, Poulos CM. A brief introduction to the use of stated-choice methods to measure preferences for treatment benefits and risks. RTI Press Publication No. RR-0009-0909. Research Triangle Park, NC: RTI International; 2009.
23. Reflection Paper on Benefit-Risk Assessment Methods in the Context of the Evaluation of Marketing Authorisation Applications of Medicinal Products for Human Use. EMEA 2008.